ad trend higher cabl invest break shop fulfil network aw secur confer
page analyst certif import disclosur
 self-servic analyt leader initi coverag buy
publish june
messag alteryx analyt vendor offer comprehens suit easi use self-servic product view transform
stori softwar leader within self-servic analyt categori emerg highli fragment space work indic alteryx
signific featur advantag tableau seat count analysi leav ampl room growth proprietari check bottom-
analysi drive posit outlook growth runway competit posit initi buy pt
 learn leader set monet power network
effect initi coverag buy
publish june
messag twenti year sinc found cornerston built command footprint user enterpris global initi
focus learn manag sinc built hcm suit next phase growth go back root becom
learn content deliveri network corpor train move push model complianc requir pull model driven
employe seek enhanc skill see proprietari analysi start fig initi coverag buy rate price
 upgrad buy fintepla nda back like
publish june
messag spoke management follow today news fintepla low dose fenfluramin nda resubmiss dravet believ
compani clear understand fda potenti approv pathway view today news new preclin studi requir
best case scenario compani also announc loss breakthrough design surpris line fda polici howev
chang view approv drug think prioriti review could help speedi approv upgrad buy
neutral pt
page analyst certif import disclosur
neutral priorit mirvetuximab dev exist
reduct extend runway
publish june
messag follow recent failur forward phase trial mirvetuximab ovarian cancner link announc today seri
restructur initi aim reduc expens extend cash runway result new plan
phase trial expect releas also priorit remain pipelin discontinu dev continu dev
w/ advanc two preclin asset monet remain portfolio platform technolog
 along joyrid
publish june
messag report anoth quarter dd growth cc end year momentum impress strength
busi believ set well anoth year top-lin outperformance/market share gain global transform invest
continu gain traction fundament remain one attract posit name opinion driven full-year dd revenu
growth cc nearli offens appar work remain buy-rat pt given favor view global
 buy stabl growth deep discount
publish june
messag bj remain one top rel growth brand casual dine given consist compstore long runway domest develop
untap low risk growth market least next year despit outlook store volum margin advanc develop share
meaning under-perform larg small cap casual dine peer posit attract restaur brand
head report period fine tune estim reflect moder near-term develop maintain price
page analyst certif import disclosur
trend expect in-lin w/top end guidanc
publish june
messag increas sale est ahead result
trajectori continu expect strong sale china particularli vaccin busi us dupix remain strong although san
among cheaper compani coverag univers maintain neutral rate given rel lacklust low-single-digit top-lin growth
increas depend dupix asthma/atop dermat growth sustain competit within hemophilia
jul better reflect san near-term busi
zg sign pa recoveri
publish june
messag focus offer see favor trend zg core premier agent pa busi highlight
chang lead distribut process spark churn deceler pa revenu zg sinc tweak process indic
cancel rate churn normal traffic zg agent portal appear bear notabl sequenti improv return
y/i growth eas comp commentari cancellations/churn data agent portal traffic increasingli comfort recoveri
 nmo go soliri bag anoth indic broad
publish june
messag spoke follow today approv soliri antibodi nmosd takeaway includ pretti broad label
carri restrict prior treatment simultan use immunosuppress soliri could monotherapi potenti treat nmosd
target patient popul like rang given exist weak standard care think nmosd indic present
larg market opportun soliri one could provid increment n-t growth opportun drug reiter pt
page analyst certif import disclosur
azn ln imfinzi sail new posit caspian
publish june
messag morn azn announc imfinzi plu chemotherapi show statist signific clinic meaning improv
os phase caspian interim analysi us posit surpris believ outcom posit imfinzi well sclc
given limit competit date sclc roch tecentriq lead given azn posit earlier stage nsclc imfinzi today news sclc
sever upcom trial adjuv later stage nsclc believ imfinzi could deliv potenti upsid vs expect
adap buy cfo rawcliff replac ceo nobl sept
potenti broader long-term strategi compani
publish june
messag today adap announc current cfo adrian rawcliff succeed jame nobl ceo effect sept mr nobl
transit non-execut director role adap board spoke management note transit plan sinc earli near-
term compani focu remain gener allogen off-the-shelf platform long-term plan broaden
cell therapi technolog car-t ph trial remain on-going updat result expect
publish june
messag report gener in-lin result adjust ep vs consensu put take
print believ investor quickli look past quarter focu compani initi guidanc
consensu mid-point expect share pressur morn trade follow disappoint outlook
page analyst certif import disclosur
 result enough today structur pressur
continu focu
publish june
messag report gener in-lin result across sale adjust oper profit share ytd vs
recent neg sentiment around space expect share see modest lift today trade back result howev
expect investor attent return reimburs trend retail pharmaci space impact gross margin well linger pressur
oper
break shop fulfil network aw secur confer result news fb support
publish june
top mind lead us smart tv market platform record per strategi analyt
cb morri look cb advertis program cost trend ahead earn see compani posit strong up-front price increas
ott expans initi
shop wong share highlight compani convers strateg rational follow better understand financi implic
near term beyond
koujalgi highlight takeaway aw secur confer see posit read-through
amladi view result mix guidanc larg line core hcm busi grow slightli slower overal industri
modest margin pressur heavier servic mix
page analyst certif import disclosur
publish june
guggenheim ndr schedul pleas scroll
ndr nj clean energi agenda dip toe jersey shore see note
keyston conemaugh coal gener interest bought arclight arm
d/ duk/ acp solicitor gener join case
duk/ north carolina/ polici storm securitization/alt rate pass third last committe hous
duk/ florida/ polici public util storm protect plan wait governor signatur
es/ psnh rate procedur schedul propos staff
north carolina/ polici nc senat bill militari base protect act pass committe public util modif
schedul updat sibley complaint docket
por/nwn oregon senat leader indic cap trade pass
polici off-shore wind itc extens introduc senat global capac possibl
page analyst certif import disclosur
inc
primari analyst jake fuller
page analyst certif import disclosur
smart final store inc
primari analyst glen santangelo
page analyst certif import disclosur
explor product
page analyst certif import disclosur
compani
page analyst certif import disclosur
